iCardiac acquires clinical trials division of nSpire Health
Financial terms of the acquisition were not disclosed. As part of the transaction, iCardiac has opened a new office in Longmont, Colorado to accommodate the project management, data management, customer support, IT, technology development and business development teams that are joining iCardiac from nSpire Health.
Alex Zapesochny, president & CEO of iCardiac, told Outsourcing-Pharma.com that the acquisition is important “as we were trying to get onto preferred provider lists, [and it] became clear that it’s important that a single provider can do cardiac safety and the spirometry component.”
For the pharma companies that require spirometry, which Zapesochny said includes seven to 10 larger users, they often value being able to go to the same source for cardiac safety and spirometry.
“iCardiac and nSpire have worked side-by-side as closely-integrated partners for over five years and on over 20 clinical trials," Zapesochny said.
nSpire Health has conducted more than 225 clinical trials over the past decade, providing centralized spirometry, pulmonary diagnostics, challenge testing, eDiary and data management services for Phase I-IV studies.
John Sage, who served as SVP of nSpire Health’s clinical division and will continue to lead respiratory and ePRO service operations at iCardiac, added: “Both current and future customers will benefit greatly from this combination of two service-oriented, technology-centered organizations.”
As far as future M&A, Zapesochny said that the company “will add some other small acquisitions in areas where we can add other services to CROs or sponsors,” and they will be “complementary to what we already offer.”
